Results 31 to 40 of about 11,103 (274)
Glucocorticoids and Mepolizumab in Eosinophilic Asthma
report that treatment with mepolizumab, a monoclonal antibody against interleukin-5, allowed a modest reduction in the maintenance dose of oral gluco -corticoids in patients who had severe eosino-philic asthma. The absolute reduction in the median dose of prednisone in the mepolizumab group was from 10.0 mg per day to 3.1 mg per day (as compared with a
Bel, E, Ortega, H, Pavord, I
openaire +7 more sources
The Role of ACT Score in Mepolizumab Discontinuation
AbstractBackgroundMepolizumab is a therapy for severe asthma. However, studies on mepolizumab with external validity and diverse population from the US are lacking. There is little knowledge of the characteristics of people that discontinue mepolizumab in clinical care.ObjectiveTo investigate the real-world efficacy and time to clinical discontinuation
Neha Solanki+14 more
openaire +2 more sources
Background Mepolizumab and benralizumab are biologics approved for severe eosinophilic asthma. Mepolizumab is an anti-interlukin-5 (IL-5) antibody while benralizumab is an anti-interleukin-5 receptor alpha (IL-5Rα) antibody targeting the IL-5 receptor on
Arian Ghassemian+3 more
doaj +1 more source
Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma [PDF]
Peer reviewedPublisher ...
Walsh, Garry Michael
core +2 more sources
Characteristics of new adult users of mepolizumab with asthma in the USA
Background In the USA, over 25 million people have asthma; 5%–10% of cases are severe. Mepolizumab (Nucala) is an interleukin-5 antagonist monoclonal antibody; it was approved by the FDA in 2015 as add-on maintenance treatment of severe asthma for ...
Pamela M McMahon+11 more
doaj +1 more source
Diagnosis and management of eosinophilic asthma: a US perspective. [PDF]
Eosinophilic asthma is now recognized as an important subphenotype of asthma based on the pattern of inflammatory cellular infiltrate in the airway. Eosinophilic asthma can be associated with increased asthma severity, atopy, late-onset disease, and ...
Doherty, Taylor A, Walford, Hannah H
core +1 more source
Churg-Strauss Syndrome with Necrosis of Toe Tips [PDF]
Churg-Strauss syndrome (CSS) is a granulomatous necrotizing vasculitis of unknown etiology associated with bronchial asthma. Despite affecting small to medium-sized vessels, necrosis of the digits due to vasculitis is extremely rare.
Hasegawa, Kenjiro+9 more
core +1 more source
Introduction Biomarkers are needed to inform the choice of biologic therapy in patients with asthma given the increasing number of biologics. We aimed to identify proteins associated with response to omalizumab and mepolizumab.
Ayobami Akenroye+4 more
doaj +1 more source
Eosinophil Apoptosis and Clearance in Asthma [PDF]
Peer reviewedPublisher ...
Bickham U.R.+9 more
core +3 more sources
Mepolizumab is primarily used in the treatment of asthma, eosinophilic granulomatosis with polyangiitis, eosinophilia syndrome, and chronic rhinitis with nasal polyps.
Fan Zou+8 more
doaj +1 more source